Chronic Kidney Disease Market Share

North America Market Analysis

North America chronic kidney disease market is set to account for revenue share of more than 42% by the end of 2037, owing to its high prevalence of chronic kidney disease and well-established infrastructure for healthcare services. Due to the high investments in CKD research and campaigns related to raising awareness, North America continues to be one of the largest markets when it comes to diagnosis and treatment options for CKD. The collaboration between public health organizations and private companies is encouraging new forms of treatment, which is driving market growth.

The U.S. chronic kidney disease market is anticipated to be driven by a high prevalence of diabetes and hypertension, favoring conditions for chronic kidney disease. In July 2022, Health Canada accepted GlaxoSmithKline's New Drug Submission for daprodustat which is an oral HIF-PHI for anemia related to underlining that the focus of North America is on advanced treatments. The demand for advanced therapies keeps growing and is reinforcing the U.S. position as one of the leading contributors to the market. The U.S. market also benefits from comprehensive insurance coverage for chronic kidney disease treatments, which allows patients in need to easily access them.

Emphasis on early diagnosis and prevention in the healthcare system propels Canada chronic kidney disease market and supportive governmental healthcare programs. The health authorities in Canada are active in the creation of chronic kidney disease awareness and early treatment, hence increasing demand for diagnostic and treatment services within the country. With this focus in place, Canada supports North America in its commitment to holistic CKD care, which makes it an integral contributor to the regional market. Also, such infrastructural setup for healthcare is firm in Canada, thereby helping early interventionists to push chronic kidney disease patients in most parts of the country.

Asia Pacific Market Analysis

Asia Pacific chronic kidney disease market is expected to grow at more than 5.5% CAGR through 2037, driven by increasing cases of diabetes and healthcare expenditure across the region, particularly in India, China, and Japan. Public health awareness campaigns also create more awareness about chronic kidney disease and its prevention, thus contributing to this region in the market. Most importantly, higher employment toward international firm practices coupled with the development of CKD diagnostics and therapies drives the emergence of the market rapidly across the geographical region.

The chronic kidney disease market in India is rising owing to the increasing incidence of diabetes and a lack of early diagnostics. Bayer launched a finerenone drug in India for chronic kidney disease patients suffering from type 2 diabetes in August 2022, which underpins this growth in demand for accessible treatments. In this respect, this development demonstrates the increasing significance of CKD care in India, where timely intervention and treatment options are incredibly important. In addition, government-backed programs to help improve rural healthcare access will continue to support growth in this market segment.

Government-driven healthcare reforms in China and growing awareness of kidney health supplement the growth of the chronic kidney disease market in the region. In May 2024, Everest Medicines launched a delayed-release capsule, Nefecon, for IgA nephropathy, one of the most common subtypes of chronic kidney disease in China. The launch indicates that the country is paying attention to the therapies for CKD, favoring regional market growth. Furthermore, the Chinese government is highly investing in healthcare technologies and infrastructures, facilitating access to innovative CKD therapies.